This led to the induction of apoptosis in AML and curbed tumor growth in PDX models.312 Nishiguchi’s development of SJ 3149, a selective and potent CK1α degrader, has shown extensive anti-proliferative effects across numerous cancer cell lines,313 expanding the therapeutic scope of selective CK1α degraders in oncology. Here, CSNK1A1 is linked to acute myeloid leukemia.